145 related articles for article (PubMed ID: 25466520)
1. Microvascular effects of the low molecular weight heparins in a colorectal xenograft model: an intravital microscopy study.
Debergh I; Pattyn P; Ceelen W
J Surg Res; 2015 Apr; 194(2):488-495. PubMed ID: 25466520
[TBL] [Abstract][Full Text] [Related]
2. The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model.
Debergh I; Van Damme N; Pattyn P; Peeters M; Ceelen WP
Br J Cancer; 2010 Mar; 102(5):837-43. PubMed ID: 20125158
[TBL] [Abstract][Full Text] [Related]
3. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer.
Simonneau G; Laporte S; Mismetti P; Derlon A; Samii K; Samama CM; Bergman JF;
J Thromb Haemost; 2006 Aug; 4(8):1693-700. PubMed ID: 16796710
[TBL] [Abstract][Full Text] [Related]
4. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
[TBL] [Abstract][Full Text] [Related]
5. Low-Molecular-Weight Heparins (LMWH) and Synthetic Factor X Inhibitors Can Impair the Osseointegration Process of a Titanium Implant in an Interventional Animal Study.
Apostu D; Berechet B; Oltean-Dan D; Mester A; Petrushev B; Popa C; Gherman ML; Tigu AB; Tomuleasa CI; Barbu-Tudoran L; Benea HRC; Piciu D
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363548
[No Abstract] [Full Text] [Related]
6. Antiangiogenic activities of bemiparin sodium, enoxaparin sodium, nadroparin calcium and tinzaparin sodium.
Dogan OT; Polat ZA; Karahan O; Epozturk K; Altun A; Akkurt I; Cetin A
Thromb Res; 2011 Oct; 128(4):e29-32. PubMed ID: 21605890
[TBL] [Abstract][Full Text] [Related]
7. Can we differentiate the low-molecular-weight heparins?
Turpie AG
Clin Cardiol; 2000 Jan; 23 Suppl 1(Suppl):I4-7. PubMed ID: 10680037
[TBL] [Abstract][Full Text] [Related]
8. Clinical safety and anticoagulation efficacy of low-molecular-weight heparins in chronic hemodialysis patients: a single medical center experience.
Chuang FR; Chen TC; Lee CH; Ng HY; Wang IK; Chang HW; Chuang PH; Wu CH; Yang CC; Su YJ
Ren Fail; 2011; 33(10):990-7. PubMed ID: 22013932
[TBL] [Abstract][Full Text] [Related]
9. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and IIa formation and on thrombelastometry profiles.
Cvirn G; Wagner T; Juergens G; Koestenberger M
Blood Coagul Fibrinolysis; 2009 Jan; 20(1):71-7. PubMed ID: 20339323
[TBL] [Abstract][Full Text] [Related]
10. Influence of low molecular weight heparin preparations on human internal thoracic artery contraction.
Buzun L; Kleszczewski T; Kostrzewska A; Lisowski P; Oleksza P; Jackowski R; Pedzińska A; Hirnle T
Eur J Cardiothorac Surg; 2004 Nov; 26(5):951-5. PubMed ID: 15519188
[TBL] [Abstract][Full Text] [Related]
11. The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.
Melsens E; Verberckmoes B; Rosseel N; Vanhove C; Descamps B; Pattyn P; Ceelen W
Eur Surg Res; 2017; 58(3-4):95-108. PubMed ID: 28002822
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the vasodilatory effect of nadroparin, enoxaparin, dalteparin, and unfractioned heparin in human internal mammary artery.
Tasatargil A; Ogutman C; Golbasi I; Karasu E; Dalaklioglu S
J Cardiovasc Pharmacol; 2005 Jun; 45(6):550-4. PubMed ID: 15897782
[TBL] [Abstract][Full Text] [Related]
13. Affinity and kinetics of different heparins binding to P- and L-selectin.
Simonis D; Christ K; Alban S; Bendas G
Semin Thromb Hemost; 2007 Jul; 33(5):534-9. PubMed ID: 17629851
[TBL] [Abstract][Full Text] [Related]
14. Effects of low molecular weight heparins and unfractionated heparin on viability of human umbilical vein endothelial cells.
Guler T; Polat ZA; Yayci E; Atacag T; Cetin A
Arch Gynecol Obstet; 2013 Feb; 287(2):217-22. PubMed ID: 22987257
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology department.
Gylys KH
J Cardiovasc Nurs; 2001 Jul; 15(4):91-5. PubMed ID: 11419668
[TBL] [Abstract][Full Text] [Related]
16. Effects of enoxaparin and nadroparin on major cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor.
Okmen E; Ozen E; Uyarel H; Sanli A; Tartan Z; Cam N
Jpn Heart J; 2003 Nov; 44(6):899-906. PubMed ID: 14711185
[TBL] [Abstract][Full Text] [Related]
17. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
Ottani F; Ferrini D; Di Pasquale G; Galvani M
Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833
[TBL] [Abstract][Full Text] [Related]
18. Fragment profiling of low molecular weight heparins using reversed phase ion pair liquid chromatography-electrospray mass spectrometry.
Xu X; Li D; Chi L; Du X; Bai X; Chi L
Carbohydr Res; 2015 Apr; 407():26-33. PubMed ID: 25701653
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.
Ajayi AA; Pharmacols FB; Cooper J; Horn EH; Rubin PC
Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):539-45. PubMed ID: 18040530
[TBL] [Abstract][Full Text] [Related]
20. Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism.
van der Wall SJ; Klok FA; den Exter PL; Barrios D; Morillo R; Cannegieter SC; Jimenez D; Huisman MV
Hemasphere; 2018; 2(1):e19. PubMed ID: 31723748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
